• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    12/4/23 5:18:06 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email
    SC 13D/A 1 tm2332044d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 13)1

    Pulse Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    74587B 10 1

    (CUSIP Number)

    ADAM W. FINERMAN, ESQ.

    BAKER HOSTETLER LLP

    45 Rockefeller Plaza

    New York, New York 10111

    (212) 589-4233

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 28, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            ROBERT W. DUGGAN  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            U.S.A  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         37,454,260*  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              37,454,260*  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            37,454,260*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            67.8%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

    * Represents (i) 37,454,260 Shares, including 197,786 Shares underlying certain options, (ii) 492,069 Shares held by Genius Inc, and (iii) 212,944 Shares held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof.

     

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            GENIUS INC.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         492,069  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              492,069  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            492,069  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0.9%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            BLAZON CORPORATION  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CALIFORNIA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         212,944  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              212,944  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            212,944  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0.4%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

     

     

     

    The following constitutes Amendment No. 13 to the Schedule 13D filed by the undersigned (the “Amendment No. 13”). This Amendment No. 13 amends the Schedule 13D as specifically set forth herein.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended and restated to read as follows:

     

    The aggregate purchase cost of the 37,454,260 Shares owned directly by Mr. Duggan is approximately $274,862,440, including brokerage commissions. Such Shares were acquired with personal funds. Mr. Duggan received his 197,786 stock options in connection with his service on the board of directors of the Issuer.  The aggregate purchase cost of the 492,069 Shares owned by Genius Inc., which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $4,471,896, including brokerage commissions. Such Shares were acquired with working capital. The aggregate purchase cost of the 212,944 Shares owned by Blazon Corporation, which Mr. Duggan is the majority shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $1,938,227, including brokerage commissions. Such Shares were acquired with working capital.

     

    Item 5.

     

    Interest in Securities of the Issuer.

    Items 5(a)-(c) are hereby amended to read as follows:

     

    The aggregate percentage of Shares reported owned by each person named herein is based upon 55,080,527 Shares outstanding as of November 15, 2023, as reported in the Company’s definitive Proxy Statement filed with the SEC on November 27, 2023.

     

      A. Genius Inc.
         
      a) As of the close of business on November 30, 2023, Genius Inc. beneficially owned 492,069 Shares.
             
            Percentage: Approximately 0.9%

     

      b) 1. Sole power to vote or direct vote: 492,069
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 492,069
         
        4. Shared power to dispose or direct the disposition: 0

      

      c) Genius Inc. has not entered into any transactions in the Shares during the past sixty days.
         
      B. Mr. Duggan
         
      a)

    As of the close of business on November 30, 2023, Mr. Duggan directly owned 37,454,260 Shares, including 197,786 Shares underlying certain options exercisable within sixty days hereof. As the sole shareholder of Genius Inc., Mr. Duggan may be deemed the beneficial owner of the 492,069 Shares owned by Genius Inc. As the majority shareholder of Blazon Corporation, Mr. Duggan may be deemed the beneficial owner of the 212,944 Shares owned by Blazon Corporation

             
            Percentage: Approximately 67.8%

     

      b) 1. Sole power to vote or direct vote: 37,454,260
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 37,454,260
         
        4. Shared power to dispose or direct the disposition: 0

     

      c)

    The transactions in the Shares by Mr. Duggan during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

     

     

     

     

      B.

    Blazon Corporation

         
      a)

    As of the close of business on November 30, 2023, Blazon Corporation beneficially owned 212,944 Shares.

             
           

    Percentage: Approximately 0.4%

     

      b) 1. Sole power to vote or direct vote: 212,944
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 212,944
         
        4. Shared power to dispose or direct the disposition: 0

     

      c)

    The transactions in the Shares by Blazon Corporation during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

     

    Transactions in the Common Stock During the Past Sixty Days
    Reporting Person Type of Security   Securities
    Purchased / (Sold)
        Price Per
    Share($)
        Date of
    Purchase / Sale
    Blazon Corporation Common Stock     152,944       9.06     11/30/2023
    Blazon Corporation Common Stock     60,000       9.21     11/29/2023
    Mr. Duggan Common Stock     1,667 *     5.95     11/29/2023
    Mr. Duggan Common Stock     158,600       9.44     11/29/2023
    Mr. Duggan Common Stock     124,397       8.98     11/28/2023
    Mr. Duggan Common Stock     241       6.10     11/17/2023
    Mr. Duggan Common Stock     10,000       6.09     11/17/2023
    Mr. Duggan Common Stock     10,000       6.11     11/17/2023
    Mr. Duggan Common Stock     13,265 *     5.95     11/7/2023

     

    *Purchased pursuant to the exercise of stock options.

      

    Item 7.Material to be Filed as Exhibits.

     

    Item 7 is hereby amended to add the following exhibit:

     

    99.1 Joint Filing Agreement, dated December 4, 2023

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: December 4, 2023

     

      GENIUS INC.
       
      By:

    /s/ Martin Bittner

        Name: Martin Bittner
        Title: Chief Operating Officer
           
      BLAZON CORPORATION
           
      By: /s/ Robert W. Duggan
        Name: Robert W. Duggan
        Title: Authorized Signatory

     

     

     

    /s/ Robert W. Duggan

      Robert W. Duggan

     

     

     

    Get the next $PLSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 8:02:46 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 6:05:11 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/13/24 7:30:48 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    See more

    $PLSE
    SEC Filings

    See more

    $PLSE
    Financials

    Live finance-specific insights

    See more
    • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

      Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

      2/4/25 8:00:00 AM ET
      $AXTA
      $PLSE
      $TFX
      Paints/Coatings
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

      Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

      10/30/24 4:02:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

      Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

      8/12/24 4:01:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Pulse Biosciences Inc

      10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 5:24:22 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 4:22:58 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Pulse Biosciences Inc

      10-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      4/30/25 9:08:54 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelect

      4/24/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

      3/27/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zanganeh Mahkam exercised 60,242 in-the-money shares at a strike of $11.00, increasing direct ownership by 9% to 725,395 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      2/11/25 6:20:57 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Laviolette Paul A

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      1/13/25 7:45:33 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Barrett Burke Thomas sold $871,000 worth of shares (50,000 units at $17.42), decreasing direct ownership by 44% to 63,172 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/20/24 5:00:42 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. Pulse Biosciences' Management is scheduled to present on Wednesday, May 14, 2025, at 5:00 pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as we

      5/6/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on April 21, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 19,500 shares of Company common stock. The Company's independent

      4/25/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

      2/10/22 6:14:40 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

      11/16/21 9:11:22 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Stephens & Co. initiated coverage on Pulse Biosciences with a new price target

      Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00

      7/27/21 5:53:59 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

      SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      7/8/24 3:30:25 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/14/23 7:21:15 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/4/23 5:18:06 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care